Latest Posts

07 Jan 2019

MEDTRONIC GETS OK TO STUDY PATIENTS WITH BICUSPID AORTIC VALUES USING COREVALVE EVOLUT TAVR SYSTEM

The U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for Medtronic to initiate a single-arm study to evaluate the CoreValve Evolut TAVR system in patients with bicuspid aortic valves who are at low risk of surgical mortality. Medtronic separately received FDA approval for revised commercial

0
07 Jan 2019

GERMAN UNIVERSITY ADDS NEW STUDY IN MEDICAL COMPUTING

  The Fraunhofer MEVIS Institute for Medical Image Computing is one of the world’s leading research centers in digital medicine. In order to prepare computer science students for challenges in this area, the Fraunhofer MEVIS Institute for Medical Image Computing and the University of Bremen in Germany are offering a

0
05 Jan 2019

WHEN MEDICINE MAKES PATIENTS SICKER

  By Sydney Lupkin Photos by Heidi de Marco Despite the jackhammer-like rhythm of a mechanical ventilator, Alicia Moreno had dozed off in a chair by her 1-year-old’s hospital bed, when a doctor woke her with some bad news: The common stool softener her son, Anderson, was given months earlier had been

0
05 Jan 2019

IT’S A LITTLE-KNOWN SECRET THAT PATIENTS CAN GET THOUSANDS OF DOLLARS DIRECTLY FROM A DRUGMAKER

      By Sarah Jane Tribble   Kip Burgess was relieved last year when pharmaceutical giant Amgen overnighted him a $2,976 check to help pay for his go-to arthritis drug, Enbrel. The 36-year-old psychologist had run into an increasingly common problem: The copay coupon sent by Thousand Oaks, Calif.-based Amgen

0
03 Jan 2019

IN.PACT ADMIRAL:  MEDTRONIC SHARES FIVE-YEAR DRUG-COATED BALLOON DATA

  Medtronic plc data presented Nov. 12 reinforce the durability, safety, and effectiveness of the IN.PACT Admiral drug-coated balloon (DCB) in patients with peripheral artery disease in the superficial femoral and popliteal arteries. The five-year and final results from the pivotal IN.PACT SFA Trial and one-year all-subjects results from the

0
SHARE

Home